{"id":"budesonide-formoterol-400-12","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that suppresses inflammatory mediators and immune cell recruitment in the lungs. Formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, improving airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:07.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT01167010","phase":"PHASE3","title":"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-04","conditions":"Asthma","enrollment":552},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT04191447","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT02972476","phase":"PHASE4","title":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT03028701","phase":"PHASE4","title":"Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2015-09","conditions":"Copd","enrollment":33},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT02766608","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-05-31","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":2389},{"nctId":"NCT01912872","phase":"PHASE4","title":"Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-11","conditions":"Severe IgE-mediated Asthma","enrollment":112},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT02725242","phase":"PHASE3","title":"Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2016-03","conditions":"Asthma","enrollment":77},{"nctId":"NCT01351792","phase":"PHASE3","title":"A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":113},{"nctId":"NCT00624754","phase":"PHASE2","title":"Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-03","conditions":"Obstructive Airway Disease","enrollment":32},{"nctId":"NCT00628758","phase":"PHASE3","title":"A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Asthma","enrollment":430},{"nctId":"NCT01181063","phase":"PHASE1","title":"Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2010-08","conditions":"Asthma","enrollment":20},{"nctId":"NCT00244608","phase":"PHASE3","title":"A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Budesonide / Formoterol 400/12","genericName":"Budesonide / Formoterol 400/12","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}